Adiponectin
Just Along for the Ride?

Aslan T. Turer, Philipp E. Scherer

A
diponectin is the most adipocyte-specific of all secretory factors described to date. Despite its exclusive expression at the level of the fat cell, adiponectin concentrations in plasma are generally inversely proportional to fat mass. More detailed studies reveal that it is not fat mass, but rather fat quality that is the driving force for adiponectin expression. Comparing metabolically healthy and metabolically unhealthy obese individuals, the metabolically healthy individuals display higher levels of adiponectin despite identical body mass indices. This reflects the close relationship between adiponectin and insulin sensitivity. Many metabolic functions of adiponectin—such as on exposure to a PPAR γ agonist—demonstrate the close relationship between adiponectin and systemic insulin sensitivity, such as on exposure to a PPAR γ (peroxisome proliferator-activated receptor gamma) agonist. We and many others concluded, therefore, that adiponectin levels are rather premature.

The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

From the Department of Internal Medicine, Division of Cardiology (A.T.T.), and Touchstone Diabetes Center (P.E.S.), University of Texas Southwestern Medical Center, Dallas. Correspondence to Philipp E. Scherer, 5323 Harry Hines Blvd, Dallas, TX 75390. E-mail philipp.scherer@utsouthwestern.edu (Circ Res. 2016;119:407-408. DOI: 10.1161/CIRCRESAHA.116.309226.) © 2016 American Heart Association, Inc.

Circulation Research is available at http://circres.ahajournals.org DOI: 10.1161/CIRCRESAHA.116.309226

The authors present a conservative analysis—consisting of single nucleotide polymorphisms (SNPs) just within the gene encoding adiponectin (ADIPOQ) itself—and a liberal analysis—consisting of other SNPs across the genome highly associated with adiponectin levels. Given that many of the SNPs in the liberal analysis are also associated with significant differences in other well-established risk factors for coronary heart disease (CHD), it seems potentially misleading to use them in the analysis in the first place because they likely reflect SNPs with broader effects on metabolism or anthropometrics. We agree with the authors that this analysis is dangerously vulnerable to horizontal pleiotropy.

The authors found that each adiponectin-increasing allele was associated with a significant decrease in CHD risk. Although this suggests that adiponectin is actually cardiometabolically protective, the authors go on to adjust for the glycemic and lipid covariates they had access to and noted no independent effect of adiponectin in protecting against CHD. One wonders whether such adjustments are necessary and indeed correct to do from a biological standpoint, given that adiponectin’s biological action is played by improving insulin sensitivity while decreasing hepatic glucose output and triglyceride accumulation. This also begs the question of how well the Mendelian randomization worked to achieve an even balance of cardiovascular risk factors across allelic groups if additional adjustment was performed.

The issue of whether the randomization was successful in achieving a balance of demographic (age, race, sex) and clinical characteristics (diabetes mellitus, smoking, hypertension, hyperlipidemia, prior CHD) germane to a CHD-outcome analysis is critical in this case, and we are not given the data to make this conclusion. Otherwise, it is not clear that any conclusions can be drawn at all. For example, adiponectin concentrations are highly related to age, race, and sex, 3 of the most important nonmodifiable CHD risk factors. It is possible, for example, that the adiponectin-increasing alleles were associated with differences in male:female ratios or different ages at CHD presentation, which would underscore a potentially protective effect that the summary data presented in the present analysis cannot discern. Further, although >90% of the study population was white, potential confounding from population stratification is still possible, and it is unclear whether any adjustment for race was performed.

As mentioned by the authors, the inability to test for the effect of prior CHD is problematic because of the well-described adiponectin paradox, whereby increasing serum adiponectin concentrations are associated with increased cardiovascular mortality among patients with existing CHD or heart failure. This poses a problem insofar as the effect of...
adiponectin on CHD outcome may be influenced by duration or severity of pre-existing CHD in an opposite way to incident cases. Ma and colleagues recently presented strong evidence for adiponectin resistance under those conditions, providing a molecular mechanism for the events taking place during heart failure.11

One important assumption of the Mendelian randomization is that the risk allele(s) can explain a reasonable amount of the variation in the intermediate factor—that is, these SNPs significantly influence the levels of adiponectin. Several ADIPOQ polymorphisms have been variably reported to influence serum adiponectin concentrations, but it is not obvious from the present analysis to what degree these polymorphisms influence adiponectin levels in circulation to a biologically meaningful degree. With the large cohorts under investigation here, even small, but perhaps clinically irrelevant, differences in adiponectin levels may be detected.

Finally, the details of adiponectin quantification are not provided. Because there is no standard assay for adiponectin (as compared with, eg, low-density lipoprotein and glucose), the values from individual cohorts generally cannot simply be joined. How statistically the authors dealt with this is not stipulated, and it is not clear whether this would have potentially influenced their findings.

We think, therefore, that the conclusions reported by Borges et al should be interpreted with great caution. The combined clinical correlational data along with strong preclinical evidence continue to support an involvement of adiponectin as a direct driving force to sustain (cardio)metabolic health.

Sources of Funding

The authors were supported by US National Institutes of Health grants R01-DK55758, R01-DK099110, and P01-DK088761 (to PE. Scherer) and Cancer Prevention Research Institute of Texas grant RP140412.

Disclosures

None.

References


Key Words: Editorials ▪ acute heart failure ▪ adiponectin ▪ adipose tissue ▪ genome-wide association scan
Adiponectin: Just Along for the Ride?
Aslan T. Turer and Philipp E. Scherer

Circ Res. 2016;119:407-408
doi: 10.1161/CIRCRESAHA.116.309226

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/119/3/407